| Literature DB >> 31440963 |
Fan Zhou1, Fen Zhou1,2, Mengyi Du1, Lin Liu1, Tao Guo1, Linghui Xia1, Runming Jin1,2, Yu Hu1, Heng Mei3.
Abstract
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by a dismal outcome. To enable better outcomes, it is necessary to develop individual therapies based on risk stratification. In the present study, we established two new comprehensive prognostic scoring systems (CPSS) for overall survival (OS) and relapse-free survival (RFS) using the Cox proportional hazards regression, CPSS integrated and weighted age, AML type, lactic dehydrogenase (LDH), ECOG score, cytogenetics, and gene mutations. We divided patients into three risk groups-low-, intermediate-, and high-risk-with 1-year OS rates of 100.0%, 82.9%, and 38.2%, respectively (p < 0.0001), and patients undergoing complete remission (CR) were also separated into low-risk, intermediate-risk, and high-risk groups, with 1-year RFS rates of 87.7%, 58.4%, and 30.2%, respectively (p < 0.0001). We conclude that CPSS that integrate clinical characteristics, cytogenetic abnormalities, and gene mutations may improve the stratification of AML patients.Entities:
Keywords: Acute myeloid leukemia (AML); Comprehensive prognostic scoring system (CPSS); Gene mutations; Next-generation sequencing (NGS); Prognosis
Mesh：
Year: 2019 PMID： 31440963 DOI： 10.1007/s12185-019-02721-y
Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490